Last reviewed · How we verify
Nadroparin calcium, warfarin
At a glance
| Generic name | Nadroparin calcium, warfarin |
|---|---|
| Also known as | Experimental group |
| Sponsor | Qilu Hospital of Shandong University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT） (PHASE4)
- Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters (PHASE3)
- Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study (PHASE3)
- Safety of Anticoagulant Therapy After Endoscopic Treatment (PHASE4)
- Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices
- Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis (PHASE4)
- Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients
- Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nadroparin calcium, warfarin CI brief — competitive landscape report
- Nadroparin calcium, warfarin updates RSS · CI watch RSS
- Qilu Hospital of Shandong University portfolio CI